Brief: Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data For Rlyb116

Rallybio

20/12/2023 13:11

Dec 20 (Reuters) - Rallybio Corp  RLYB.O :
    * RALLYBIO ANNOUNCES PRELIMINARY PHASE 1 MULTIPLE ASCENDING
DOSE
DATA FOR RLYB116, AN INNOVATIVE SUBCUTANEOUSLY INJECTED
INHIBITOR OF COMPLEMENT COMPONENT 5
    * RALLYBIO CORP - 100 MG RESULTS DEMONSTRATED A MEAN
REDUCTION OF
GREATER THAN 93% IN FREE C5 WITH LOW VOLUME ONCE-A-WEEK
SUBCUTANEOUS DOSING
    * RALLYBIO CORP - DATA SUPPORTS STUDY OF RLYB116 AS A
DIFFERENTIATED THERAPEUTIC FOR TREATMENT OF GENERALIZED
MYASTHENIA GRAVIS
    * RALLYBIO CORP - ANNOUNCES EXTENSION OF RUNWAY TO 3Q 2025
AS PART
OF PORTFOLIO PRIORITIZATION
    * RALLYBIO CORP - COMPANY INTENDS TO PRIORITIZE NEAR-TERM
INVESTMENTS IN RLYB116 IN MANUFACTURING PROCESS

Source text for Eikon:  ID:nBw8Tl5zTa 
Further company coverage:  RLYB.O 

 ((Reuters.Briefs@thomsonreuters.com;))